Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine.
about
The role of HPV in head and neck cancer and review of the HPV vaccineRole of the microbiome in non-gastrointestinal cancersPreventive vaccination against cervical cancer: Korean Society of Gynecologic Oncology GuidelineSafety and Efficacy Data on Vaccines and Immunization to Human PapillomavirusHarnessing immunosurveillance: current developments and future directions in cancer immunotherapyLong-term efficacy and safety of human papillomavirus vaccinationAn enhanced heterologous virus-like particle for human papillomavirus type 16 tumour immunotherapy.Safety of human papillomavirus vaccines: a review.Synthesis and characterization of different immunogenic viral nanoconstructs from rotavirus VP6 inner capsid protein.The potential impact of HPV-16 reactivation on prevalence in older Australians.Measurement of neutralizing serum antibodies of patients vaccinated with human papillomavirus L1 or L2-based immunogens using furin-cleaved HPV Pseudovirions.Persistent antibodies to HPV virus-like particles following natural infection are protective against subsequent cervicovaginal infection with related and unrelated HPV.Cost-effectiveness analysis of different types of human papillomavirus vaccination combined with a cervical cancer screening program in mainland ChinaImpact of smoking on the quantity and quality of antibodies induced by human papillomavirus type 16 and 18 AS04-adjuvanted virus-like-particle vaccine - a pilot studyVaccination with HPV16 L2E6E7 fusion protein in GPI-0100 adjuvant elicits protective humoral and cell-mediated immunity.Alternative dosage schedules with HPV virus-like particle vaccines.In vivo mechanisms of vaccine-induced protection against HPV infection.The levels of anti-HPV16/18 and anti-HPV31/33/35/45/52/58 antibodies among AS04-adjuvanted HPV16/18 vaccinated and non-vaccinated Ugandan girls aged 10-16 yearsPerspective for prophylaxis and treatment of cervical cancer: an immunological approach.Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial data.The efficacy and duration of vaccine protection against human papillomavirus: a systematic review and meta-analysis.Prevention of cervical, vaginal, and vulval cancers: role of the quadrivalent human papillomavirus (6, 11, 16, 18) recombinant vaccineHPV vaccine: an overview of immune response, clinical protection, and new approaches for the future.Characteristics of memory B cells elicited by a highly efficacious HPV vaccine in subjects with no pre-existing immunityHPV vaccine acceptance, utilization and expected impacts in the U.S.: Where are we now?Safety and immunogenicity of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine in HIV-infected children 7 to 12 years old.Human papillomavirus disease and vaccines in adolescents.Human papilloma virus vaccination: impact and recommendations across the world.Prevention of cancer by prophylactic human papillomavirus vaccines.Developing vaccines against minor capsid antigen L2 to prevent papillomavirus infection.Health economic analysis of human papillomavirus vaccines in women of Chile: perspective of the health care payer using a Markov modelThe breadth and potency of passively acquired human immunodeficiency virus type 1-specific neutralizing antibodies do not correlate with the risk of infant infection.End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24-45 years of age.Systematic review and meta-analysis of L1-VLP-based human papillomavirus vaccine efficacy against anogenital pre-cancer in women with evidence of prior HPV exposure.HPV - immune response to infection and vaccinationComparing bivalent and quadrivalent human papillomavirus vaccines: economic evaluation based on transmission model.Paradigm shifting vaccines: prophylactic vaccines against latent varicella-zoster virus infection and against HPV-associated cancerHuman papilloma virus vaccines: Current scenarioImmunogenicity of the quadrivalent human papillomavirus (type 6/11/16/18) vaccine in males 16 to 26 years oldEvidence of immune memory 8.5 years following administration of a prophylactic human papillomavirus type 16 vaccine.
P2860
Q24630128-EBDC6659-C8BD-4D3E-9AB4-80AA29FE1235Q26747710-BC266490-4253-481D-ABCD-631E5BAE044AQ26749285-1038820A-F65A-4C24-9D4F-EC51FE57171FQ26799574-D65EBAED-C9E7-4352-831C-2E21EF729E90Q27021570-3D9A5A09-B356-4136-A946-8DCCB9001DFFQ28081156-C5D039C7-8287-414A-8F01-A39083C9D7C7Q31121276-9519218A-C1E1-460C-A9FE-647D87555C45Q33162724-4F6441B3-EC03-4019-BDA5-8653461840C1Q33720570-03666970-BA1F-4A86-80D1-B096BCE1CEE6Q33769284-45F75574-BA03-42B1-AD48-38FF19C6BEB5Q33856453-405C94E9-F3E9-4AE7-B615-4F95A6213455Q33905022-7D293B9B-B18B-4EE4-9416-B4F5AEB5413CQ33916649-E8842FFB-818F-4F33-884E-14CF95274BCCQ33929216-542EC18F-3682-4B5E-A56A-CEB236E5B6D4Q34078674-E87F4955-C0FB-481F-896F-92094EF29675Q34102466-EAD5FEA6-B2B3-4C59-AA92-429142AA772AQ34125906-AEAF689F-1F59-4B3C-B4F4-08D00DD484B5Q34152234-26B89991-9A24-49F6-ADA1-3BD8C972B99AQ34181909-AFA19627-D741-4469-A21F-92A5340EFD86Q34210255-89FB5DAA-F0DA-4871-8D67-20C808E3F027Q34241823-6B2D0B1B-92AC-47CA-8B67-ED993171852DQ34272071-DF64AA36-3ADF-4FB1-9AB3-3C857E183584Q34335370-041AB4C4-E520-437D-804D-D6BE0B8242AAQ34352416-9B3E7BD8-BD62-460A-8112-89A37295D5B9Q34440994-15A3435E-B8CC-43B4-8E35-547F365CAAB1Q34549645-ABDF92AA-4514-4AE2-8CBE-42AB1E669ABEQ34675079-CB5B1513-BEF0-40E7-BB02-A24180EB7E61Q34704575-CBB38AC3-3581-4DCC-8CE6-73D3BD6430C5Q34762053-6C17CB4A-D2A1-4CB5-B054-2661A53364B8Q34786808-92E2F7D8-D052-4598-B9A1-12EC3374857DQ34894228-9148C213-06F4-4752-A36E-65B3DB072BAAQ34982698-CC457E97-3B93-48B5-A0FC-3EA2A2E8E952Q35108338-CDA543F5-FA56-4130-8946-91492C45E194Q35111092-820FFBFA-F503-40EB-A0C5-9071B41B6047Q35180148-FC63274C-D0DF-4E81-BC53-474BBD993663Q35235306-9DEA0320-3096-4B05-B849-43F115AAD2E0Q35258843-554446C2-1C30-48BD-9C21-76C766033B3CQ35366075-005E02F7-6E7B-430A-954A-8EF0E709B34AQ35739048-84C3A3E2-D9D9-498B-B146-05396418B861Q35757389-B274B947-BB23-435F-99AA-04E5479AE727
P2860
Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
Induction of immune memory fol ...... s-like particle (VLP) vaccine.
@en
Induction of immune memory fol ...... drivalent human papillomavirus
@nl
type
label
Induction of immune memory fol ...... s-like particle (VLP) vaccine.
@en
Induction of immune memory fol ...... drivalent human papillomavirus
@nl
prefLabel
Induction of immune memory fol ...... s-like particle (VLP) vaccine.
@en
Induction of immune memory fol ...... drivalent human papillomavirus
@nl
P2093
P1433
P1476
Induction of immune memory fol ...... s-like particle (VLP) vaccine.
@en
P2093
Agneta Andersson-Ellstrom
Alfred J Saah
Carlos A Petta
Christian Malm
Eliav Barr
Geo von Krogh
Gretchen M Tamms
Grete Riis-Johannessen
Katherine Giacoletti
P304
P356
10.1016/J.VACCINE.2007.03.049
P407
P577
2007-04-20T00:00:00Z